Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — Jefferies Healthcare Conference 2023
18 slides from Amneal Pharmaceuticals's conference presentation, Jun 7, 2023
Slide 1: Amneal Pharmaceuticals
Amneal Pharmaceuticals Chirag Patel, Co-founder & Co-CEO Jefferies Healthcare Conference g June 7, 2023
Slide 2: Cautionary Statement on Forward Looking Statements
Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements reg
Slide 3: Amneal Pharmaceuticals – We make healthy possible
Amneal Pharmaceuticals – We make healthy possible® • Global diversified pharmaceuticals company with a growing portfolio of ~270 products across Retail Generics, Injectables, Biosimilars and Specialty, and an expanding AvKARE distribution business • Highly productive R&D engine focused on complex an
Slide 4: Substantial revenue and profitability growth driven by diversified portfolio and new product innovation
Substantial revenue and profitability growth driven by diversified portfolio and new product innovation (1) Net Revenue Growth Adjusted EBITDA Growth ($ millions) Mid-single ($ millions) $2,500 digit growth $2,250 - $2,350 $500-$530 +6% $2,212 $514 +22% $2,094 $512 +5% Mid-single +4% $1,993 digit gr
Slide 5: Clear long-term growth strategy
Clear long-term growth strategy 2022 Business area Strategy for growth Growth projection(1) Net Revenue Retail Grow #4 U.S. Generics portfolio of ~230 products with new Low-single digit growth Generics launches and shift to complex dosage forms Expand portfolio of ~30 institutional products through
Slide 6: Significant growth catalysts across portfolio
Significant growth catalysts across portfolio Retail Injectables Biosimilars Specialty International Recently Launched Launched Launched Filed NDA with FDA Signed completed ✓ Azacitidine, Prochlorperazine ✓ Lurasidone, Colesevelam ✓ ALYMSYS®, a ✓ IPX203 ✓ European distribution Edisylate, Nelarabine
Slide 7: Business at scale – with capabilities from R&D to distribution
Business at scale – with capabilities from R&D to distribution Capabilities R&D Manufacturing Commercial Distribution Retail Generics Innovating across dosage forms, Produce vast majority of Trusted relationships and industry particularly complex products in-house leading customer service Injectable
Slide 8: Differentiated R&D and manufacturing capabilities
Differentiated R&D and manufacturing capabilities Best-in-class R&D and manufacturing capabilities Global network of FDA-approved, delivering complex & high-value dosage forms cGMP manufacturing sites INJECTABLES TRANSDERMALS ORAL SOLIDS, & STERILE LIQUIDS & TOPICALS Matrix Peptides Hydrogel IR/ER t
Slide 9: Affordable medicines generating sustainable, profitable growth
GENERICS Affordable medicines generating sustainable, profitable growth Regularly refreshing & diversifying Generics portfolio ~81 pipeline programs with ~$38B TAM Innovative R&D pipeline drives 20-30 new launches per year RETAIL INJECTABLES ~99 • #4 U.S. Generics business • ~30 institutional produc
Slide 10: Transforming our specialty business with expanding portfolio
SPECIALTY Transforming our specialty business with expanding portfolio Build on strength in key brands Potential Launch Program Therapeutic Area Specialty highlights to achieve $500M+ sales by 2027 Q3’23 IPX203 Parkinson’s ($ millions) $500+ 2025 K-127 Myasthenia Gravis • Therapeutic focus on Neurol
Slide 11: IPX203 presents novel formulation of extended-release CD/LD
SPECIALTY IPX203 presents novel formulation of extended-release CD/LD CD/LD market represents over 3 million prescriptions each year for Parkinson’s Disease patients Potential benefits of IPX203 Expanding CD/LD market share for IPX203 Clear opportunity to drive broader adoption of IPX203 to the full
Slide 12: Delivering double-digit growth in AvKARE business
AVKARE Delivering double-digit growth in AvKARE business $406 AvKARE distribution channel $48 expansion driving rapid growth ($ millions) $349 $38 • Operates as a contract administrator (wholesaler $294 $98 and re-packager selling to hospitals and U.S. $28 Government agencies) with three business un
Slide 13: International expansion expected to drive incremental upside
INTERNATIONAL International expansion expected to drive incremental upside Entering key global markets to drive incremental revenue & cash flow from U.S. FDA approved portfolio Geography Direct / Partner Strategy and status India Direct • Utilizing commercial team to launch Expanding local products
Slide 14: Our financial narrative calls for accelerated growth
Our financial narrative calls for accelerated growth Generics Specialty AvKARE Total Company High-single digit growth High-single digit growth with Double-digit growth High-single digit growth Accelerated revenue driven by complex generics expanding portfolio from IPX203 in line with growth with all
Slide 15: Fast-growing global pharmaceuticals company providing essential medicines
Fast-growing global pharmaceuticals company providing essential medicines with compelling value proposition Diversified and growing portfolio of essential medicines with multiple paths to accelerated growth across business Expansive global capabilities across R&D, manufacturing and commercial to dri
Slide 16: Appendix: Non-GAAP Reconciliations
Appendix: Non-GAAP Reconciliations
Slide 17: Reconciliation of net (loss) income to adjusted EBITDA
Reconciliation of net (loss) income to adjusted EBITDA Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. 17
Slide 18: Reconciliation of Last Twelve Months Adjusted EBITDA
Reconciliation of Last Twelve Months Adjusted EBITDA (1) Refer to the Company's 8-K filed with the SEC on March 2, 2023 for a complete reconciliation of our GAAP to non-GAAP results. (2) Refer to the Company's 8-K filed with the SEC on May 4, 2022 for a complete reconciliation of our GAAP to non-GAA
Amneal Pharmaceuticals — Jefferies Healthcare Conference 2023 on 6ix